Last reviewed · How we verify
Ceresine (DICHLOROACETIC ACID)
Ceresine (generic name: DICHLOROACETIC ACID) is a dichloroacetic acid drug. It is currently in Phase 3 development for Verruca.
Ceresine works by inhibiting an enzyme involved in energy production in cells, which can help to treat warts.
Ceresine, also known as dichloroacetic acid, is a small molecule drug that targets pyruvate dehydrogenase (acetyl-transferring) kinase isozyme 2, mitochondrial. It is used to treat verruca, a type of wart. The commercial status of Ceresine is unknown, and it is not FDA-approved. Key safety considerations include its short half-life of 0.65 hours. Further research is needed to fully understand its pharmacology and potential side effects.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DICHLOROACETIC ACID |
|---|---|
| Drug class | dichloroacetic acid |
| Target | [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your cells are like factories that produce energy. Ceresine blocks a key step in this process, which can help to slow down the growth of abnormal cells that cause warts. This can help to reduce the size and appearance of warts over time.
Approved indications
- Verruca
Common side effects
Key clinical trials
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) (PHASE2)
- Regulation of Brain Glucose Metabolism in Type 1 Diabetes (EARLY_PHASE1)
- Expanded Access Treatment Protocol With DCA for Patients With PDCD
- Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (PHASE3)
- A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain (NA)
- Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers (PHASE1)
- Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes (EARLY_PHASE1)
- Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceresine CI brief — competitive landscape report
- Ceresine updates RSS · CI watch RSS
Frequently asked questions about Ceresine
What is Ceresine?
How does Ceresine work?
What is Ceresine used for?
What is the generic name of Ceresine?
What drug class is Ceresine in?
What development phase is Ceresine in?
What does Ceresine target?
Related
- Drug class: All dichloroacetic acid drugs
- Target: All drugs targeting [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial
- Therapeutic area: All drugs in Other
- Indication: Drugs for Verruca
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing